Renal amyloidosis epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
 
(12 intermediate revisions by 3 users not shown)
Line 2: Line 2:
{{Renal Amyloidosis}}
{{Renal Amyloidosis}}


{{CMG}}; {{AE}} {{SHH}}
{{CMG}}; {{AE}} {{SHH}} [[User:Okamal|Omer Kamal, M.D.]] [Mailto:okamal@bidmc.harvard.edu| <nowiki>[2]</nowiki>]
==Overview==
==Overview==
The incidence is 0.97 to 1.4 cases per 100,000 person-years. The prevalence of AL amyloidosis was 40.5 in 2015, an annual percentage change (APC) of 12%. In renal amyloidosis, is usually first diagnosed in average age of 65 years and it is uncommon before age of 40.


==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Incidence===
===Incidence===
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
The incidence is 0.97 to 1.4 cases per 100,000 person-years.<ref name="pmid29748430">{{cite journal |vauthors=Quock TP, Yan T, Chang E, Guthrie S, Broder MS |title=Epidemiology of AL amyloidosis: a real-world study using US claims data |journal=Blood Adv |volume=2 |issue=10 |pages=1046–1053 |date=May 2018 |pmid=29748430 |pmc=5965052 |doi=10.1182/bloodadvances.2018016402 |url=}}</ref>
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.


===Prevalence===
===Prevalence===
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
The prevalence of AL amyloidosis was 40.5 in 2015, an annual percentage change (APC) of 12%. <ref name="pmid29748430" />
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
*The prevalence of [disease/malignancy] is estimated to be [number] cases annually.


===Mortality rate===
===Mortality rate===
*In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
*AL has higher mortality than AA type<ref name="pmid18184882">{{cite journal |vauthors=Bollée G, Guery B, Joly D, Snanoudj R, Terrier B, Allouache M, Mercadal L, Peraldi MN, Viron B, Fumeron C, Elie C, Fakhouri F |title=Presentation and outcome of patients with systemic amyloidosis undergoing dialysis |journal=Clin J Am Soc Nephrol |volume=3 |issue=2 |pages=375–81 |date=March 2008 |pmid=18184882 |pmc=2390937 |doi=10.2215/CJN.02470607 |url=}}</ref>
*The case-fatality rate/mortality rate of [disease name] is approximately [number range].


===Age===
===Age===
*In renal amyloidosis, is usually first diagnosed in average age of 65 years.
* The incidence of renal amyloidosis increases with age; the median age at diagnosis is 65 years.<ref name="pmid25852856">{{cite journal |vauthors=Khalighi MA, Dean Wallace W, Palma-Diaz MF |title=Amyloid nephropathy |journal=Clin Kidney J |volume=7 |issue=2 |pages=97–106 |date=April 2014 |pmid=25852856 |pmc=4377792 |doi=10.1093/ckj/sfu021 |url=}}</ref><ref name="pmid27942184">{{cite journal |vauthors=Hajra A, Bandyopadhyay D |title=An interesting case of renal amyloidosis |journal=Indian J Nephrol |volume=26 |issue=6 |pages=467–469 |date=2016 |pmid=27942184 |pmc=5131391 |doi=10.4103/0971-4065.177143 |url=}}</ref>


===Race===
===Race===
*There is no racial predilection to [disease name].
*There is no racial predilection to renal amyloidosis.
*[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
===Gender===
===Gender===
*In renal amyloidosis, the male to female ratio is approximately 2 to 1.
*Males are are more commonly affected by renal amyloidosis.
*The male to female ratio is approximately 2 to 1.<ref name="pmid25852856" />


===Region===
===Region===
*The majority of [disease name] cases are reported in [geographical region].
*ALECT2 is more frequent in the United States area.<ref name="pmid23704299">{{cite journal |vauthors=Said SM, Sethi S, Valeri AM, Leung N, Cornell LD, Fidler ME, Herrera Hernandez L, Vrana JA, Theis JD, Quint PS, Dogan A, Nasr SH |title=Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases |journal=Clin J Am Soc Nephrol |volume=8 |issue=9 |pages=1515–23 |date=September 2013 |pmid=23704299 |pmc=3805078 |doi=10.2215/CJN.10491012 |url=}}</ref>
 
*AFib cases are most reported in Europe countries.
*[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
 
===Developed Countries===
 
===Developing Countries===


==References==
==References==

Latest revision as of 15:50, 9 August 2018

Renal amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Renal amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography or Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Template:Renal amyloidosis On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Renal amyloidosis epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Renal amyloidosis epidemiology and demographics

CDC on Renal amyloidosis epidemiology and demographics

Renal amyloidosis epidemiology and demographics in the news

Blogs on Renal amyloidosis epidemiology and demographics

Directions to Hospitals Treating Cystic fibrosis

Risk calculators and risk factors for Renal amyloidosis epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2] Omer Kamal, M.D. [2]

Overview

The incidence is 0.97 to 1.4 cases per 100,000 person-years. The prevalence of AL amyloidosis was 40.5 in 2015, an annual percentage change (APC) of 12%. In renal amyloidosis, is usually first diagnosed in average age of 65 years and it is uncommon before age of 40.

Epidemiology and Demographics

Incidence

The incidence is 0.97 to 1.4 cases per 100,000 person-years.[1]

Prevalence

The prevalence of AL amyloidosis was 40.5 in 2015, an annual percentage change (APC) of 12%. [1]

Mortality rate

  • AL has higher mortality than AA type[2]

Age

  • The incidence of renal amyloidosis increases with age; the median age at diagnosis is 65 years.[3][4]

Race

  • There is no racial predilection to renal amyloidosis.

Gender

  • Males are are more commonly affected by renal amyloidosis.
  • The male to female ratio is approximately 2 to 1.[3]

Region

  • ALECT2 is more frequent in the United States area.[5]
  • AFib cases are most reported in Europe countries.

References

  1. 1.0 1.1 Quock TP, Yan T, Chang E, Guthrie S, Broder MS (May 2018). "Epidemiology of AL amyloidosis: a real-world study using US claims data". Blood Adv. 2 (10): 1046–1053. doi:10.1182/bloodadvances.2018016402. PMC 5965052. PMID 29748430.
  2. Bollée G, Guery B, Joly D, Snanoudj R, Terrier B, Allouache M, Mercadal L, Peraldi MN, Viron B, Fumeron C, Elie C, Fakhouri F (March 2008). "Presentation and outcome of patients with systemic amyloidosis undergoing dialysis". Clin J Am Soc Nephrol. 3 (2): 375–81. doi:10.2215/CJN.02470607. PMC 2390937. PMID 18184882.
  3. 3.0 3.1 Khalighi MA, Dean Wallace W, Palma-Diaz MF (April 2014). "Amyloid nephropathy". Clin Kidney J. 7 (2): 97–106. doi:10.1093/ckj/sfu021. PMC 4377792. PMID 25852856.
  4. Hajra A, Bandyopadhyay D (2016). "An interesting case of renal amyloidosis". Indian J Nephrol. 26 (6): 467–469. doi:10.4103/0971-4065.177143. PMC 5131391. PMID 27942184.
  5. Said SM, Sethi S, Valeri AM, Leung N, Cornell LD, Fidler ME, Herrera Hernandez L, Vrana JA, Theis JD, Quint PS, Dogan A, Nasr SH (September 2013). "Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases". Clin J Am Soc Nephrol. 8 (9): 1515–23. doi:10.2215/CJN.10491012. PMC 3805078. PMID 23704299.

Template:WH Template:WS